DOSSIER · UPDATED 18 NOV 2025

Versanis Bio

Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen…

versanisbio.com ↗Claim this profile
Founded
2021
Headcount
17
Open roles
0
Last raised
Series A · $70M
SECTION I · THE BRIEF

Inside Versanis Bio

Brief #09266Updated 18 NOV 2025OAKLANDMEDICAL ORGANIZATIONSSERIES A
Employbl Dossier

Versanis Bio

Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more…

Founded
2021
Headcount
17
Open roles
0
Last raised
Series A · $70M
Section II — RestrictedMembers only
  • Tech stack (Versanis Bio engineering primaries)
  • Hiring focus this quarter
  • Interview format & rubric
  • Comp bands by level
  • Decision-makers in talent
  • Recent news & moves
Open Versanis Bio briefSign in

7-day free trial · $25/mo · cancel anytime

TAGS

Categorized in

Company Collections

These are collections Versanis Bio is a part of. Click on the collection name to view similar companies.

Versanis Bio's Industries

Versanis Bio's Tech Stack

LOCATIONS

Where they work

Versanis Bio Headquarters Location

1111 Broadway Suite 1300, Oakland, CA, 94607

Loading map…
FUNDING

Capital raised

Total Amount Raised: $70,000,000

Versanis Bio Funding Rounds

  • Series A

    $70,000,000

  • Series A

    $70,000,000

    Series A Investors

    Atlas Venture
    Medicxi Ventures (UK)
    Aditum Bio
    TCG Crossover Management
Funding info provided by Diffbot.
EMPLOYEE REVIEWS

On the ground at Versanis Bio

Versanis Bio Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Versanis Bio.

Recent reviews